SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Nostrand Robert L. Van Purchases 10,000 Shares

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) Director Nostrand Robert L. Van purchased 10,000 shares of SELLAS Life Sciences Group stock in a transaction that occurred on Thursday, June 12th. The shares were bought at an average price of $1.48 per share, for a total transaction of $14,800.00. Following the transaction, the director now directly owns 20,400 shares of the company's stock, valued at $30,192. This trade represents a 96.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

SELLAS Life Sciences Group Stock Performance

Shares of SLS traded down $0.05 on Monday, reaching $1.61. The stock had a trading volume of 1,775,694 shares, compared to its average volume of 1,590,572. SELLAS Life Sciences Group, Inc. has a 12-month low of $0.77 and a 12-month high of $2.12. The firm has a market capitalization of $160.64 million, a price-to-earnings ratio of -2.33 and a beta of 2.25. The company has a 50-day simple moving average of $1.53 and a 200-day simple moving average of $1.27.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.04. On average, analysts expect that SELLAS Life Sciences Group, Inc. will post -0.57 EPS for the current fiscal year.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Hedge funds have recently bought and sold shares of the business. Virtu Financial LLC increased its stake in shares of SELLAS Life Sciences Group by 30.9% during the first quarter. Virtu Financial LLC now owns 53,861 shares of the company's stock valued at $58,000 after purchasing an additional 12,706 shares in the last quarter. Northern Trust Corp grew its stake in shares of SELLAS Life Sciences Group by 33.6% in the 4th quarter. Northern Trust Corp now owns 134,721 shares of the company's stock worth $140,000 after buying an additional 33,878 shares during the last quarter. Opus Capital Group LLC increased its position in SELLAS Life Sciences Group by 5.5% during the 4th quarter. Opus Capital Group LLC now owns 238,500 shares of the company's stock valued at $248,000 after buying an additional 12,400 shares in the last quarter. Brooklyn FI LLC purchased a new position in SELLAS Life Sciences Group during the fourth quarter valued at $677,000. Finally, Geode Capital Management LLC boosted its holdings in SELLAS Life Sciences Group by 21.2% in the fourth quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock worth $763,000 after acquiring an additional 128,355 shares in the last quarter. Institutional investors own 17.38% of the company's stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.